<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34032984</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2509-2723</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>GeroScience</Title><ISOAbbreviation>Geroscience</ISOAbbreviation></Journal><ArticleTitle>Regulation of TDP-43 phosphorylation in aging and disease.</ArticleTitle><Pagination><StartPage>1605</StartPage><EndPage>1614</EndPage><MedlinePgn>1605-1614</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s11357-021-00383-5</ELocationID><Abstract><AbstractText>Insoluble inclusions of phosphorylated TDP-43 occur in disease-affected neurons of most patients with amyotrophic lateral sclerosis (ALS) and about half of patients with frontotemporal lobar degeneration (FTLD-TDP). Phosphorylated TDP-43 potentiates a number of neurotoxic effects including reduced liquid-liquid phase separation dynamicity, changes in splicing, cytoplasmic mislocalization, and aggregation. Accumulating evidence suggests a balance of kinase and phosphatase activities control TDP-43 phosphorylation. Dysregulation of these processes may lead to an increase in phosphorylated TDP-43, ultimately contributing to neurotoxicity and neurodegeneration in disease. Here we summarize the evolving understanding of major regulators of TDP-43 phosphorylation as well as downstream consequences of their activities. Interventions restoring kinase and phosphatase balance may be a generalizable therapeutic strategy for all TDP-43 proteinopathies including ALS and FTLD-TDP.</AbstractText><CopyrightInformation>&#xa9; 2021. This is a U.S. government work and not under copyright protection in the U.S.; foreign copyright protection may apply.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Eck</LastName><ForeName>Randall J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of Washington, Seattle, WA, 98195, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center, Seattle Veterans Affairs Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA, 98108, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kraemer</LastName><ForeName>Brian C</ForeName><Initials>BC</Initials><AffiliationInfo><Affiliation>Neuroscience Graduate Program, University of Washington, Seattle, WA, 98195, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center, Seattle Veterans Affairs Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA, 98108, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington, Seattle, WA, 98104, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, WA, 98195, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Laboratory Medicine &amp; Pathology, University of Washington, Seattle, WA, 98104, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liachko</LastName><ForeName>Nicole F</ForeName><Initials>NF</Initials><Identifier Source="ORCID">0000-0003-1250-3871</Identifier><AffiliationInfo><Affiliation>Geriatric Research Education and Clinical Center, Seattle Veterans Affairs Puget Sound Health Care System, 1660 South Columbian Way, Seattle, WA, 98108, USA. nliachko@uw.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Gerontology and Geriatric Medicine, Department of Medicine, University of Washington, Seattle, WA, 98104, USA. nliachko@uw.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>I01 BX002619</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS064131</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>I01 BX004044</GrantID><Acronym>BX</Acronym><Agency>BLRD VA</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>05</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Geroscience</MedlineTA><NlmUniqueID>101686284</NlmUniqueID><ISSNLinking>2509-2723</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010766" MajorTopicYN="N">Phosphorylation</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Amyotrophic lateral sclerosis (ALS)</Keyword><Keyword MajorTopicYN="N">Frontotemporal lobar degeneration (FTLD)</Keyword><Keyword MajorTopicYN="N">Kinases</Keyword><Keyword MajorTopicYN="N">Phosphatases</Keyword><Keyword MajorTopicYN="N">Phosphorylation</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword></KeywordList><CoiStatement>The authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>2</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>5</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>25</Day><Hour>14</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34032984</ArticleId><ArticleId IdType="pmc">PMC8492835</ArticleId><ArticleId IdType="doi">10.1007/s11357-021-00383-5</ArticleId><ArticleId IdType="pii">10.1007/s11357-021-00383-5</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ou SH, et al. Cloning and characterization of a novel cellular protein, TDP-43, that binds to human immunodeficiency virus type 1 TAR DNA sequence motifs. J Virol. 1995;69(6):3584&#x2013;3596. doi: 10.1128/jvi.69.6.3584-3596.1995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.69.6.3584-3596.1995</ArticleId><ArticleId IdType="pmc">PMC189073</ArticleId><ArticleId IdType="pubmed">7745706</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero EN, et al. TDP-43/FUS in motor neuron disease: complexity and challenges. Prog Neurobiol. 2016;145&#x2013;146:78&#x2013;97. doi: 10.1016/j.pneurobio.2016.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2016.09.004</ArticleId><ArticleId IdType="pmc">PMC5101148</ArticleId><ArticleId IdType="pubmed">27693252</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314(5796):130&#x2013;133. doi: 10.1126/science.1134108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1134108</ArticleId><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, et al. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351(3):602&#x2013;611. doi: 10.1016/j.bbrc.2006.10.093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2006.10.093</ArticleId><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasegawa M, et al. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008;64(1):60&#x2013;70. doi: 10.1002/ana.21425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21425</ArticleId><ArticleId IdType="pmc">PMC2674108</ArticleId><ArticleId IdType="pubmed">18546284</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E. Functional significance of TDP-43 mutations in disease. Adv Genet. 2015;91:1&#x2013;53. doi: 10.1016/bs.adgen.2015.07.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/bs.adgen.2015.07.001</ArticleId><ArticleId IdType="pubmed">26410029</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR. The neuropathology of FTD associated With ALS. Alzheimer Dis Assoc Disord. 2007;21(4):S44&#x2013;S49. doi: 10.1097/WAD.0b013e31815c3486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/WAD.0b013e31815c3486</ArticleId><ArticleId IdType="pubmed">18090423</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawakami I, Arai T, Hasegawa M. The basis of clinicopathological heterogeneity in TDP-43 proteinopathy. Acta Neuropathol. 2019;138(5):751&#x2013;770. doi: 10.1007/s00401-019-02077-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-019-02077-x</ArticleId><ArticleId IdType="pmc">PMC6800885</ArticleId><ArticleId IdType="pubmed">31555895</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann DMA, Snowden JS. Frontotemporal lobar degeneration: Pathogenesis, pathology and pathways to phenotype. Brain Pathol. 2017;27(6):723&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029341</ArticleId><ArticleId IdType="pubmed">28100023</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117(2):137&#x2013;149. doi: 10.1007/s00401-008-0477-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-008-0477-9</ArticleId><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>McAleese KE, et al. TDP-43 pathology in Alzheimer&#x2019;s disease, dementia with Lewy bodies and ageing. Brain Pathol. 2017;27(4):472&#x2013;479. doi: 10.1111/bpa.12424.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12424</ArticleId><ArticleId IdType="pmc">PMC8029292</ArticleId><ArticleId IdType="pubmed">27495267</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, et al. Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. Ann Neurol. 2015;77(6):942&#x2013;952. doi: 10.1002/ana.24388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.24388</ArticleId><ArticleId IdType="pmc">PMC4447563</ArticleId><ArticleId IdType="pubmed">25707479</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, et al. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer&#x2019;s disease. Ann Neurol. 2007;61(5):435&#x2013;445. doi: 10.1002/ana.21154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.21154</ArticleId><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>James BD, et al. TDP-43 stage, mixed pathologies, and clinical Alzheimer&#x2019;s-type dementia. Brain. 2016;139(11):2983&#x2013;2993. doi: 10.1093/brain/aww224.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/aww224</ArticleId><ArticleId IdType="pmc">PMC5091047</ArticleId><ArticleId IdType="pubmed">27694152</ArticleId></ArticleIdList></Reference><Reference><Citation>Uryu K, et al. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol. 2008;67(6):555&#x2013;564. doi: 10.1097/NEN.0b013e31817713b5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31817713b5</ArticleId><ArticleId IdType="pmc">PMC3659339</ArticleId><ArticleId IdType="pubmed">18520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakashima-Yasuda H, et al. Co-morbidity of TDP-43 proteinopathy in Lewy body related diseases. Acta Neuropathol. 2007;114(3):221&#x2013;229. doi: 10.1007/s00401-007-0261-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-007-0261-2</ArticleId><ArticleId IdType="pubmed">17653732</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab C, et al. Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J Neuropathol Exp Neurol. 2008;67(12):1159&#x2013;1165. doi: 10.1097/NEN.0b013e31818e8951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e31818e8951</ArticleId><ArticleId IdType="pubmed">19018245</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovacs GG, et al. Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. Acta Neuropathol. 2013;126(3):365&#x2013;384. doi: 10.1007/s00401-013-1157-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-013-1157-y</ArticleId><ArticleId IdType="pubmed">23900711</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, et al. TDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy. J Neuropathol Exp Neurol. 2010;69(9):918&#x2013;929. doi: 10.1097/NEN.0b013e3181ee7d85.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/NEN.0b013e3181ee7d85</ArticleId><ArticleId IdType="pmc">PMC2951281</ArticleId><ArticleId IdType="pubmed">20720505</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, et al. TDP-43 and limbic-predominant age-related TDP-43 encephalopathy. Front Aging Neurosci. 2019;11:376. doi: 10.3389/fnagi.2019.00376.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fnagi.2019.00376</ArticleId><ArticleId IdType="pmc">PMC6971113</ArticleId><ArticleId IdType="pubmed">31992981</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, et al. Human, Drosophila, and C.elegans TDP43: nucleic acid binding properties and splicing regulatory function. J Mol Biol. 2005;348(3):575&#x2013;88. doi: 10.1016/j.jmb.2005.02.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2005.02.038</ArticleId><ArticleId IdType="pubmed">15826655</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinarbasi ES, et al. Active nuclear import and passive nuclear export are the primary determinants of TDP-43 localization. Sci Rep. 2018;8(1):7083. doi: 10.1038/s41598-018-25008-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-018-25008-4</ArticleId><ArticleId IdType="pmc">PMC5935693</ArticleId><ArticleId IdType="pubmed">29728608</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang CK, et al. The N-terminus of TDP-43 promotes its oligomerization and enhances DNA binding affinity. Biochem Biophys Res Commun. 2012;425(2):219&#x2013;224. doi: 10.1016/j.bbrc.2012.07.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2012.07.071</ArticleId><ArticleId IdType="pubmed">22835933</ArticleId></ArticleIdList></Reference><Reference><Citation>Afroz T, et al. Functional and dynamic polymerization of the ALS-linked protein TDP-43 antagonizes its pathologic aggregation. Nat Commun. 2017;8(1):45. doi: 10.1038/s41467-017-00062-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-017-00062-0</ArticleId><ArticleId IdType="pmc">PMC5491494</ArticleId><ArticleId IdType="pubmed">28663553</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin H, et al. TDP-43 N terminus encodes a novel ubiquitin-like fold and its unfolded form in equilibrium that can be shifted by binding to ssDNA. Proc Natl Acad Sci U S A. 2014;111(52):18619&#x2013;18624. doi: 10.1073/pnas.1413994112.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1413994112</ArticleId><ArticleId IdType="pmc">PMC4284588</ArticleId><ArticleId IdType="pubmed">25503365</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE. Characterization and functional implications of the RNA binding properties of nuclear factor TDP-43, a novel splicing regulator of CFTR exon 9. J Biol Chem. 2001;276(39):36337&#x2013;36343. doi: 10.1074/jbc.M104236200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M104236200</ArticleId><ArticleId IdType="pubmed">11470789</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo PH, et al. Structural insights into TDP-43 in nucleic-acid binding and domain interactions. Nucleic Acids Res. 2009;37(6):1799&#x2013;1808. doi: 10.1093/nar/gkp013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkp013</ArticleId><ArticleId IdType="pmc">PMC2665213</ArticleId><ArticleId IdType="pubmed">19174564</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo PH, et al. The crystal structure of TDP-43 RRM1-DNA complex reveals the specific recognition for UG- and TG-rich nucleic acids. Nucleic Acids Res. 2014;42(7):4712&#x2013;4722. doi: 10.1093/nar/gkt1407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkt1407</ArticleId><ArticleId IdType="pmc">PMC3985631</ArticleId><ArticleId IdType="pubmed">24464995</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa Y, et al. A molecular mechanism realizing sequence-specific recognition of nucleic acids by TDP-43. Sci Rep. 2016;6:20576. doi: 10.1038/srep20576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep20576</ArticleId><ArticleId IdType="pmc">PMC4738331</ArticleId><ArticleId IdType="pubmed">26838063</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen HJ, et al. RRM adjacent TARDBP mutations disrupt RNA binding and enhance TDP-43 proteinopathy. Brain. 2019;142(12):3753&#x2013;3770. doi: 10.1093/brain/awz313.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/brain/awz313</ArticleId><ArticleId IdType="pmc">PMC6885686</ArticleId><ArticleId IdType="pubmed">31605140</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, et al. The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat Med. 2016;22(8):869&#x2013;878. doi: 10.1038/nm.4130.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4130</ArticleId><ArticleId IdType="pmc">PMC4974139</ArticleId><ArticleId IdType="pubmed">27348499</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, et al. Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci. 2008;121(Pt 22):3778&#x2013;3785. doi: 10.1242/jcs.038950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1242/jcs.038950</ArticleId><ArticleId IdType="pubmed">18957508</ArticleId></ArticleIdList></Reference><Reference><Citation>Colombrita C, et al. TDP-43 is recruited to stress granules in conditions of oxidative insult. J Neurochem. 2009;111(4):1051&#x2013;1061. doi: 10.1111/j.1471-4159.2009.06383.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06383.x</ArticleId><ArticleId IdType="pubmed">19765185</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella AE, et al. TDP-43 alpha-helical structure tunes liquid-liquid phase separation and function. Proc Natl Acad Sci U S A. 2020;117(11):5883&#x2013;5894. doi: 10.1073/pnas.1912055117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1912055117</ArticleId><ArticleId IdType="pmc">PMC7084079</ArticleId><ArticleId IdType="pubmed">32132204</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella AE, et al. ALS Mutations disrupt phase separation mediated by alpha-helical structure in the TDP-43 low-complexity C-terminal domain. Structure. 2016;24(9):1537&#x2013;1549. doi: 10.1016/j.str.2016.07.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.str.2016.07.007</ArticleId><ArticleId IdType="pmc">PMC5014597</ArticleId><ArticleId IdType="pubmed">27545621</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, et al. TDP-43 is intrinsically aggregation-prone and ALS-linked mutations accelerate aggregation and increase toxicity. J Biol Chem. 2009;284(30):20329&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim L, et al. ALS-causing mutations significantly perturb the self-assembly and interaction with nucleic acid of the intrinsically disordered prion-like domain of TDP-43. PLoS Biol. 2016;14(1):e1002338. doi: 10.1371/journal.pbio.1002338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pbio.1002338</ArticleId><ArticleId IdType="pmc">PMC4703307</ArticleId><ArticleId IdType="pubmed">26735904</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt HB, Rohatgi R. In vivo formation of vacuolated multi-phase compartments lacking membranes. Cell Rep. 2016;16(5):1228&#x2013;1236. doi: 10.1016/j.celrep.2016.06.088.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2016.06.088</ArticleId><ArticleId IdType="pmc">PMC4972689</ArticleId><ArticleId IdType="pubmed">27452472</ArticleId></ArticleIdList></Reference><Reference><Citation>Fuentealba RA, et al. Interaction with polyglutamine aggregates reveals a Q/N-rich domain in TDP-43. J Biol Chem. 2010;285(34):26304&#x2013;26314. doi: 10.1074/jbc.M110.125039.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.125039</ArticleId><ArticleId IdType="pmc">PMC2924052</ArticleId><ArticleId IdType="pubmed">20554523</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassel JA, Reitz AB. Ubiquilin-2 (UBQLN2) binds with high affinity to the C-terminal region of TDP-43 and modulates TDP-43 levels in H4 cells: characterization of inhibition by nucleic acids and 4-aminoquinolines. Biochim Biophys Acta. 2013;1834(6):964&#x2013;971. doi: 10.1016/j.bbapap.2013.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2013.03.020</ArticleId><ArticleId IdType="pmc">PMC3960997</ArticleId><ArticleId IdType="pubmed">23541532</ArticleId></ArticleIdList></Reference><Reference><Citation>Buratti E, Baralle FE. TDP-43: gumming up neurons through protein-protein and protein-RNA interactions. Trends Biochem Sci. 2012;37(6):237&#x2013;247. doi: 10.1016/j.tibs.2012.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tibs.2012.03.003</ArticleId><ArticleId IdType="pubmed">22534659</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen TJ, et al. An acetylation switch controls TDP-43 function and aggregation propensity. Nat Commun. 2015;6:5845. doi: 10.1038/ncomms6845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms6845</ArticleId><ArticleId IdType="pmc">PMC4407365</ArticleId><ArticleId IdType="pubmed">25556531</ArticleId></ArticleIdList></Reference><Reference><Citation>Seyfried NT, et al. Multiplex SILAC analysis of a cellular TDP-43 proteinopathy model reveals protein inclusions associated with SUMOylation and diverse polyubiquitin chains. Mol Cell Proteomics. 2010;9(4):705&#x2013;718. doi: 10.1074/mcp.M800390-MCP200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/mcp.M800390-MCP200</ArticleId><ArticleId IdType="pmc">PMC2860236</ArticleId><ArticleId IdType="pubmed">20047951</ArticleId></ArticleIdList></Reference><Reference><Citation>Inukai Y, et al. Abnormal phosphorylation of Ser409/410 of TDP-43 in FTLD-U and ALS. FEBS Lett. 2008;582(19):2899&#x2013;2904. doi: 10.1016/j.febslet.2008.07.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2008.07.027</ArticleId><ArticleId IdType="pubmed">18656473</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F, et al. Mass spectrometric analysis of accumulated TDP-43 in amyotrophic lateral sclerosis brains. Sci Rep. 2016;6:23281. doi: 10.1038/srep23281.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep23281</ArticleId><ArticleId IdType="pmc">PMC4793195</ArticleId><ArticleId IdType="pubmed">26980269</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Antibody against TDP-43 phosphorylated at serine 375 suggests conformational differences of TDP-43 aggregates among FTLD-TDP subtypes. Acta Neuropathol. 2020;140(5):645&#x2013;658. doi: 10.1007/s00401-020-02207-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02207-w</ArticleId><ArticleId IdType="pmc">PMC7547034</ArticleId><ArticleId IdType="pubmed">32778941</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, et al. Correction to: Antibody against TDP-43 phosphorylated at serine 369 suggests conformational differences of TDP-43 aggregates among FTLD-TDP subtypes. Acta Neuropathol. 2021;141(1):137. doi: 10.1007/s00401-020-02242-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-020-02242-7</ArticleId><ArticleId IdType="pmc">PMC7852961</ArticleId><ArticleId IdType="pubmed">33141274</ArticleId></ArticleIdList></Reference><Reference><Citation>Liachko NF, et al. CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration. Ann Neurol. 2013;74(1):39&#x2013;52. doi: 10.1002/ana.23870.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.23870</ArticleId><ArticleId IdType="pmc">PMC3775949</ArticleId><ArticleId IdType="pubmed">23424178</ArticleId></ArticleIdList></Reference><Reference><Citation>Liachko NF, et al. The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43. PLoS Genet. 2014;10(12):e1004803. doi: 10.1371/journal.pgen.1004803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1004803</ArticleId><ArticleId IdType="pmc">PMC4256087</ArticleId><ArticleId IdType="pubmed">25473830</ArticleId></ArticleIdList></Reference><Reference><Citation>Kametani F, et al. Identification of casein kinase-1 phosphorylation sites on TDP-43. Biochem Biophys Res Commun. 2009;382(2):405&#x2013;409. doi: 10.1016/j.bbrc.2009.03.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2009.03.038</ArticleId><ArticleId IdType="pubmed">19285963</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlomagno Y, et al. Casein kinase II induced polymerization of soluble TDP-43 into filaments is inhibited by heat shock proteins. PLoS One. 2014;9(3):e90452. doi: 10.1371/journal.pone.0090452.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0090452</ArticleId><ArticleId IdType="pmc">PMC3942448</ArticleId><ArticleId IdType="pubmed">24595055</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor LM, et al. Pathological phosphorylation of tau and TDP-43 by TTBK1 and TTBK2 drives neurodegeneration. Mol Neurodegener. 2018;13(1):7. doi: 10.1186/s13024-018-0237-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-018-0237-9</ArticleId><ArticleId IdType="pmc">PMC5802059</ArticleId><ArticleId IdType="pubmed">29409526</ArticleId></ArticleIdList></Reference><Reference><Citation>Salado IG, et al. Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis. J Med Chem. 2014;57(6):2755&#x2013;2772. doi: 10.1021/jm500065f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm500065f</ArticleId><ArticleId IdType="pmc">PMC3969104</ArticleId><ArticleId IdType="pubmed">24592867</ArticleId></ArticleIdList></Reference><Reference><Citation>Rojas-Prats E, et al. Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis. Eur J Med Chem. 2021;210:112968. doi: 10.1016/j.ejmech.2020.112968.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmech.2020.112968</ArticleId><ArticleId IdType="pubmed">33139113</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Gonzalez L, et al. Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1delta kinase inhibitor treatment. Sci Rep. 2020;10(1):4449. doi: 10.1038/s41598-020-61265-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-61265-y</ArticleId><ArticleId IdType="pmc">PMC7064575</ArticleId><ArticleId IdType="pubmed">32157143</ArticleId></ArticleIdList></Reference><Reference><Citation>Alquezar C, et al. Targeting TDP-43 phosphorylation by Casein Kinase-1delta inhibitors: a novel strategy for the treatment of frontotemporal dementia. Mol Neurodegener. 2016;11(1):36. doi: 10.1186/s13024-016-0102-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13024-016-0102-7</ArticleId><ArticleId IdType="pmc">PMC4852436</ArticleId><ArticleId IdType="pubmed">27138926</ArticleId></ArticleIdList></Reference><Reference><Citation>Krach F, et al. Transcriptome-pathology correlation identifies interplay between TDP-43 and the expression of its kinase CK1E in sporadic ALS. Acta Neuropathol. 2018;136(3):405&#x2013;423. doi: 10.1007/s00401-018-1870-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-018-1870-7</ArticleId><ArticleId IdType="pmc">PMC6215775</ArticleId><ArticleId IdType="pubmed">29881994</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, et al. Heat shock-induced phosphorylation of TAR DNA-binding protein 43 (TDP-43) by MAPK/ERK kinase regulates TDP-43 function. J Biol Chem. 2017;292(12):5089&#x2013;5100. doi: 10.1074/jbc.M116.753913.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M116.753913</ArticleId><ArticleId IdType="pmc">PMC5377819</ArticleId><ArticleId IdType="pubmed">28167528</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, et al. Protein phosphatase 1 dephosphorylates TDP-43 and suppresses its function in tau exon 10 inclusion. FEBS Lett. 2018;592(3):402&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">29334120</ArticleId></ArticleIdList></Reference><Reference><Citation>Liachko NF, et al. The phosphatase calcineurin regulates pathological TDP-43 phosphorylation. Acta Neuropathol. 2016;132(4):545&#x2013;561. doi: 10.1007/s00401-016-1600-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-016-1600-y</ArticleId><ArticleId IdType="pmc">PMC5026939</ArticleId><ArticleId IdType="pubmed">27473149</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis SA, et al. TDP-43 expression influences amyloidbeta plaque deposition and tau aggregation. Neurobiol Dis. 2017;103:154&#x2013;162. doi: 10.1016/j.nbd.2017.04.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2017.04.012</ArticleId><ArticleId IdType="pmc">PMC5544914</ArticleId><ArticleId IdType="pubmed">28416393</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferri A, et al. Activity of protein phosphatase calcineurin is decreased in sporadic and familial amyotrophic lateral sclerosispatients. J Neurochem. 2004;90(5):1237&#x2013;1242. doi: 10.1111/j.1471-4159.2004.02588.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02588.x</ArticleId><ArticleId IdType="pubmed">15312178</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagey R, Krieger C, Shaw CA. Abnormal dephosphorylation effect on NMDA receptor regulation in ALS spinal cord. Neurobiol Dis. 1997;4(5):350&#x2013;355. doi: 10.1006/nbdi.1997.0145.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.1997.0145</ArticleId><ArticleId IdType="pubmed">9440123</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang A, et al. A single N-terminal phosphomimic disrupts TDP-43 polymerization, phase separation, and RNA splicing. EMBO J. 2018;37(5):e97452.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5830921</ArticleId><ArticleId IdType="pubmed">29438978</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun L, et al. TAR DNA binding protein-43 loss of function induced by phosphorylation at S409/410 blocks autophagic flux and participates in secondary brain injury after intracerebral hemorrhage. Front Cell Neurosci. 2018;12:79. doi: 10.3389/fncel.2018.00079.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fncel.2018.00079</ArticleId><ArticleId IdType="pmc">PMC5874314</ArticleId><ArticleId IdType="pubmed">29623031</ArticleId></ArticleIdList></Reference><Reference><Citation>Hicks DA, et al. Endoplasmic reticulum stress signalling induces casein kinase 1-dependent formation of cytosolic TDP-43 inclusions in motor neuron-like cells. Neurochem Res. 2020;45(6):1354&#x2013;1364. doi: 10.1007/s11064-019-02832-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-019-02832-2</ArticleId><ArticleId IdType="pmc">PMC7260270</ArticleId><ArticleId IdType="pubmed">31280399</ArticleId></ArticleIdList></Reference><Reference><Citation>Newell K, et al. Dysregulation of TDP-43 intracellular localization and early onset ALS are associated with a TARDBP S375G variant. Brain Pathol. 2019;29(3):397&#x2013;413. doi: 10.1111/bpa.12680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bpa.12680</ArticleId><ArticleId IdType="pmc">PMC6875182</ArticleId><ArticleId IdType="pubmed">30461104</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F, et al. Cytoplasmic TDP-43 De-mixing Independent of stress granules drives inhibition of nuclear import, loss of nuclear TDP-43, and cell death. Neuron. 2019;102(2):339&#x2013;57 e7. doi: 10.1016/j.neuron.2019.02.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.02.038</ArticleId><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AK, et al. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol. 2015;130(5):643&#x2013;660. doi: 10.1007/s00401-015-1460-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-015-1460-x</ArticleId><ArticleId IdType="pmc">PMC5127391</ArticleId><ArticleId IdType="pubmed">26197969</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu H, et al. HSP70 chaperones RNA-free TDP-43 into anisotropic intranuclear liquid spherical shells. Science. 2021;371(6529):eabb4309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8286096</ArticleId><ArticleId IdType="pubmed">33335017</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, et al. Phosphorylation regulates proteasomal-mediated degradation and solubility of TAR DNA binding protein-43 C-terminal fragments. Mol Neurodegener. 2010;5:33. doi: 10.1186/1750-1326-5-33.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1750-1326-5-33</ArticleId><ArticleId IdType="pmc">PMC2941488</ArticleId><ArticleId IdType="pubmed">20804554</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T, Teramoto S, Kwak S. Phosphorylated TDP-43 becomes resistant to cleavage by calpain: A regulatory role for phosphorylation in TDP-43 pathology of ALS/FTLD. Neurosci Res. 2016;107:63&#x2013;69. doi: 10.1016/j.neures.2015.12.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neures.2015.12.006</ArticleId><ArticleId IdType="pubmed">26723245</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamashita T, et al. A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. Nat Commun. 2012;3:1307. doi: 10.1038/ncomms2303.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms2303</ArticleId><ArticleId IdType="pubmed">23250437</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, et al. Phosphorylation of TAR DNA-binding protein of 43 kDa (TDP-43) by truncated casein kinase 1delta triggers mislocalization and accumulation of TDP-43. J Biol Chem. 2016;291(11):5473&#x2013;5483. doi: 10.1074/jbc.M115.695379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M115.695379</ArticleId><ArticleId IdType="pmc">PMC4786690</ArticleId><ArticleId IdType="pubmed">26769969</ArticleId></ArticleIdList></Reference><Reference><Citation>Nonaka T, et al. Prion-like properties of pathological TDP-43 aggregates from diseased brains. Cell Rep. 2013;4(1):124&#x2013;134. doi: 10.1016/j.celrep.2013.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2013.06.007</ArticleId><ArticleId IdType="pubmed">23831027</ArticleId></ArticleIdList></Reference><Reference><Citation>Brady OA, et al. Regulation of TDP-43 aggregation by phosphorylation and p62/SQSTM1. J Neurochem. 2011;116(2):248&#x2013;259. doi: 10.1111/j.1471-4159.2010.07098.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2010.07098.x</ArticleId><ArticleId IdType="pubmed">21062285</ArticleId></ArticleIdList></Reference><Reference><Citation>Li HY, et al. Hyperphosphorylation as a defense mechanism to reduce TDP-43 aggregation. PLoS One. 2011;6(8):e23075. doi: 10.1371/journal.pone.0023075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0023075</ArticleId><ArticleId IdType="pmc">PMC3151276</ArticleId><ArticleId IdType="pubmed">21850253</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR, et al. RNA binding antagonizes neurotoxic phase transitions of TDP-43. Neuron. 2019;102(2):321&#x2013;338 e8. doi: 10.1016/j.neuron.2019.01.048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2019.01.048</ArticleId><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang P, et al. Chronic optogenetic induction of stress granules is cytotoxic and reveals the evolution of ALS-FTD pathology. Elife. 2019;8:e39578.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6426440</ArticleId><ArticleId IdType="pubmed">30893049</ArticleId></ArticleIdList></Reference><Reference><Citation>McGurk L, et al. Poly(ADP-Ribose) prevents pathological phase separation of TDP-43 by promoting liquid demixing and stress granule localization. Mol Cell. 2018;71(5):703&#x2013;717 e9. doi: 10.1016/j.molcel.2018.07.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molcel.2018.07.002</ArticleId><ArticleId IdType="pmc">PMC6128762</ArticleId><ArticleId IdType="pubmed">30100264</ArticleId></ArticleIdList></Reference><Reference><Citation>Liachko NF, Guthrie CR, Kraemer BC. Phosphorylation promotes neurotoxicity in a Caenorhabditis elegans model of TDP-43 proteinopathy. J Neurosci. 2010;30(48):16208&#x2013;16219. doi: 10.1523/JNEUROSCI.2911-10.2010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.2911-10.2010</ArticleId><ArticleId IdType="pmc">PMC3075589</ArticleId><ArticleId IdType="pubmed">21123567</ArticleId></ArticleIdList></Reference><Reference><Citation>Choksi DK, et al. TDP-43 Phosphorylation by casein kinase I&#x3b5; promotes oligomerization and enhances toxicity in vivo. Hum Mol Genet. 2014;23(4):1025&#x2013;1035. doi: 10.1093/hmg/ddt498.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddt498</ArticleId><ArticleId IdType="pubmed">24105464</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>